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ABSTRACT 
Metabolomics is an exciting field in systems biology which provides a direct signature of the 
biochemical activities in an individual at a particular time point.  Metabolite levels are influenced by 
many factors including disease status, environment, medications, diet and, importantly, genetics. 
Their dynamic nature makes them useful for diagnosis or prognosis as well as for predicting and 
monitoring treatment efficacy. At the same time the strong links to genetic variation allows 
investigation of pathways underlying changes in their levels. Thus, for metabolomics to yield its full 
potential, the stable genetic contribution to metabolites and how these link to disease processes 
needs to be better understood.  Here we discuss methodological aspects related to metabolomic 
profiling. We then review the metabolomic and genetic studies carried out to date on rheumatologic 
traits and investigate any potential links to the genetics of some of the most common rheumatologic 
disorders, as well as links to new fields like the gut microbiome. 
  
3 
 
INTRODUCTION  
Metabolomics is a high-throughput technology that  captures the global metabolic state of an 
individual by assaying simultaneously an extensive set of  low-molecular-weight compounds 
(metabolites) in a biological sample1. Metabolites can be considered as the intermediate outcome of 
a number of physiological processes including disease processes, lifestyle, environmental exposure, 
pharmacological treatments and others (Figure 1). In this sense, metabolites are closer to the actual 
disease phenotype (e.g.  rheumatoid arthritis) than genetic variation, gene expression levels or 
protein levels. This makes metabolomics a powerful tool to identify biomarkers that can be used as 
diagnosis or to improve prognosis and predict and monitor treatment efficacy, as has been done for 
systemic autoimmune diseases2. Moreover, clinical response to therapy has been shown to result in 
different metabolite profiles3 suggesting that metabolomic profiling helps to identify responders to 
therapy and to improve clinical management of rheumatologic disorders. Metabolomic profiling has 
therefore the potential to provide an alternative perspective of the altered molecular processes 
responsible for the onset and pathogenesis of various forms of rheumatologic disease and this can 
be of paramount importance to prevent joint damage and disability. 
At the same time, metabolite levels are also influenced by an individual’s genetic makeup4-9. In order 
for metabolomics to yield its full potential the genetic contribution to metabolites and to disease 
processes needs to be more fully addressed. In this review we cover first the various methodological 
aspects related to metabolomic profiling. We then review the metabolomic and genetics studies 
carried to date on selected rheumatologic traits. Finally, we investigate any potential links to the 
genetics of some of the most common rheumatologic disorders including rheumatoid arthritis (RA), 
osteoarthritis (OA), psoriasis arthritis (PsA), gout and systemic lupus erythematosus (SLE).  
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TECHNOLOGICAL STRENGTHS AND LIMITATIONS 
Targeted versus untargeted identification 
Thousands of small molecules make up the human metabolome10 and the precise number of 
independent metabolites potentially detectable is still unclear. Although it is now possible to 
characterise hundreds of known metabolites, it is not yet possible to get a full coverage of the 
metabolome. There are two approaches to measure the metabolome: targeted and untargeted 
(Figure 2) 11,12. Untargeted metabolomics platforms can measure hundreds of metabolites with the 
advantage of detecting previously unpredicted metabolic perturbations associated with a certain 
disease. No a priori knowledge on biologically relevant metabolites is required when designing this 
type of experiments, similar to genome-wide association studies. These approaches are useful to 
find novel mechanisms or biomarkers. Targeted approaches, on the other hand, resemble candidate 
gene association study where a smaller and pre-defined set is measured, typically focusing on a few 
pathways of interest. Advantages include higher sensitivity and absolute (instead of relative) 
quantification and easy compound identification11.  
Analytical tools 
Metabolites vary in size, polarity and concentration making unbiased detection, identification and 
quantification of the whole metabolome technically challenging10. Metabolomics is mainly achieved 
by either high nuclear magnetic resonance (NMR) spectroscopy or mass spectrometry (MS)13-15 as 
recently reviewed16.  
Briefly, NMR spectroscopy is a quantitative non-discriminating, non-destructive, perturbing 
technique that gives detailed information on solution-state molecular structures, based on atom-
centred nuclear interactions. There are several advantages to NMR which include its potential for 
high-throughput measure, the minimal requirements for sample preparation, reproducibility of the 
results, the low cost of the measurement, the speed of data acquisition and the non-discriminating 
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and non-destructive nature of the technique. However, it has relatively low sensitivity and can 
detect only medium to high abundance metabolites.  
On the other hand, MS based metabolomics provides quantitative analyses with high selectivity and 
sensitivity and the potential to identify metabolites. Samples are initially separated using 
chromatography (e.g. gas chromatography (GC), capillary electrophoresis (CE) or liquid/ultra 
performance liquid chromatography (LC/UPLC)) and then identified with a mass spectrometer17,18  
although pre-separation is not always required and there are commercial MS kits  (Biocrates) that  
use direct sampling from plates without pre-separation for quantitative analysis.  MS methods 
provide metabolite separation in a time dimension, from which highly specific chemical information 
can be extracted.  However, MS-based techniques require preparation steps that can be very 
elaborate and may cause metabolite loss. Also, different platforms can detect different metabolites 
and therefore, parallel application of techniques, for example, GC-MS and LC-MS is desired to study 
the metabolome comprehensively.   
Sample Type 
Metabolomics profiling can be conducted on a variety of biological samples, ranging from urine and 
blood, to faeces, synovial fluid (SF), saliva, organ tissues, specific cells, tumours, etc. 
Urine and blood (serum and plasma) are the most accessible bio-samples, they can be easily and 
minimally invasively collected in both cases and controls. Also, there is no need for 
grinding/fractionation. However, they may not reflect biochemical changes in the joint, nor be 
directly linked to physiologic pathological changes in the joint. 
For rheumatologic disorders, synovial fluid and tissues from either the joint or the bone are also very 
relevant.  . SF samples are easy to collect from RA and OA patients with effusion, although less so 
from unaffected controls.  This type of fluid has a lower need for processing and sample preparation 
than other types of tissue-derived samples (e.g. cartilage, bone). On the other hand, the 
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metabolomics profile in SF may not fully reflect biochemical changes in other joint tissues such as 
bone/cartilage/tendons. 
 Tissues from the joint/bone are very useful when studying pathogenic processes in the joint. Those 
however are extremely challenging to collect in large numbers particularly for controls. Moreover, 
LC/MS often requires manual extraction, solvent extraction of tissue samples precipitation and 
further re-dissolving of dry residues (Figure 3). 
How to deal with ‘unknown’ molecules 
Untargeted metabolomics approaches also provide quantification of metabolites whose chemical 
identity has not yet been identified, though can be reproducibly detected and quantified. These 
metabolites, the so-called unknowns, have a big impact on biomedical research as many of them 
show strong correlations with clinical phenotypes19-21 but their use as functional biomarkers is clearly 
very limited. The majority of studies ignores the unknowns either by platform design22 or at the 
analysis stage23,24. Others have tried to solve the problem by employing different computer based 
methods to try and uncover the unknown true identity. Genetic data is particularly useful in this 
sense as several unknown metabolites are associated with genetic variation5,7 and the strong genetic 
association can provide some clue on the metabolic pathway the unknown is most likely to be in. 
Building on this, Krumsiek and colleagues, developed a novel functional metabolomics method to 
predict unknown metabolites identity, integrating high-throughput genotyping data, metabolomics 
data and pathways information derived from the literature25. The advantage of their method is that 
it can be applied to metabolomics database obtain from commercial service, for which retention 
times, isotope patterns and fragmentation are not readily available. 
ANALYTICAL STRENGTHS AND LIMITATIONS  
Statistical techniques: data reduction, pathway analysis  
Different statistical techniques can be employed in the analysis of metabolomics data (Figure 4)26.  
7 
 
Usually the starting point is quality control of the metabolite data which may involve several steps 
including  (i) data normalisation to remove/reduce the unwanted overall variation in the spectral 
data, (ii) standardising the data so that the data distribution has a mean of  0 when data is measured 
in a relative manner and (iii) scaling to account for different levels of concentration across 
metabolites with a focus on those with medium/ low-concentration. After this univariate and 
multivariate statistical analyses are performed to identify candidate biomarkers. Univariate analyses, 
such as linear model, t-test or ANOVA, examine each variable separately and are particularly 
adequate when the aim is to identify metabolites associated with disease pathogenesis . Stringent 
multiple testing correction is normally applied (Bonferroni/False Discovery Rate), which can obscure 
some biologically relevant observation. However, despite this obvious limitations including type 2 
errors, they produce very solid and reproducible results. 
Multivariate analysis is powerful for classification and prediction since one biomarker alone 
might not be by itself specific for a given trait. Multivariate methods range from principal 
component analysis (PCA), partial least squares - discriminant analysis (PLS-DA), penalised 
regression, random forest  and support vector machine (SVM)27. PCA is particularly useful to get an 
overview of the data and to define previously unknown relationship between metabolites in a given 
physiological state.  On the other hand, supervised methods such as PLS SVM can be used to build a 
model for classification. Most of the multivariate methods need full data matrices which introduces 
the problem of imputation. 
Independent replication and functional studies are especially important to validate the results.  
While biomarkers are useful for risk prediction and health assessment, the value of a biomarker 
increases substantially if it is causally involved in the manifestation of a condition such as OA/RA etc. 
Causality can only be proven experimentally but multi-omics data allow for interesting modelling 
and statistical inference of causality. The genetic effect is by definition causal so combining genetic 
and metabolomics data may allow to infer causality networks of the phenotypes. Metabolic 
associations are difficult to understand in complex traits28. Using omics technologies helps to 
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decipher the biological meaning of otherwise obscure statistical associations. Benefits of the use of 
pathway and ontological analyses of genomics data have been extensively presented29,30. Analysis of 
biological pathways using the Database for Annotation, Visualisation and Integrated Discovery 
(DAVID) v6.731 and the Ingenuity Pathway analysis (IPA)32 can be used to identify potential pathways 
determining metabolite signatures associated with particular conditions. Indeed these functional 
annotation tools used for genomic/genetic studies can be applied to the genes identified via GWAS 
or transcriptomics as associated with the metabolites under study and hence provide information on 
the pathways linked to these disease or drug response associated metabolites. 
 
Open-source data repositories 
Several open-source data repositories, as well as open access databases containing chemical, 
biological, molecular information about metabolites are now available. These include the Human 
Metabolon Database (HMDB)10, PubChem33, the Kyoto Encyclopedia of Genes and Genomes 
(KEGG)34, the Metabolic Pathway Database (MetaCyc)35, the Chemical Entities of Biological Interest 
database (ChEBI)36, MetaboLIGHTS37 and the metabolomics  genome-wide association studies 
(GWAS http://mips.helmholtz-muenchen.de/proj/GWAS/gwas/) server, among others. 
Moreover, web services have been developed for metabolomic data processing, analysis and 
annotation (e.g. MetaboAnalyst http://www.metaboanalyst.ca/faces/home.xhtml) 
METABOLOMICS AND GENOMICS FOR RHEUMATOLOGIC TRAITS   
A number of studies in the past few years have mapped genetic variation to plasma, serum and urine 
metabolites and have highlighted the genetic influence on these traits4-9. Also, using metabolomics 
as a readout of molecular phenotypes allows the discovery of formerly undetected associations 
between diseases, genes and metabolic pathways. The number of metabolomics studies has 
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exponentially increased (Figure 5) with over 4000 papers published in 2015, a quota not much lower 
than that of GWAS papers. 
 
Metabolome  
In the past few years various studies investigated the associations of rheumatic diseases with human 
metabolites (Table 1 and Supplementary Table 1). These studies have shown that patients can be 
clearly distinguished from healthy controls based on the metabolic profile of blood22 as well as 
urine38 . Using a panel of 52 metabolites measured in circulating blood Madsen and colleagues39  
could accurately distinguish between RA patients and healthy controls as well as PsA patients. The 
authors found that patients could be distinguished from controls by decreased levels of (branched-
chain) amino acids20,40, increased levels of 3-hydroxybutyrate and lactate41 and significant changes of  
energy metabolism42,43. Interestingly, similar metabolic changes also correlated with disease severity 
and response to treatment44,45. For instance,  Kapoor and collaborators3 predicted the response to 
anti-TNF therapy based on urine metabolite profiles with a sensitivity of 88.9% and specificity of 
85.7%. Metabolomics studies also helped to identify causal mechanisms of disease, e.g. by 
establishing the role of pro-inflammatory estrogens46, as well as the estrogens receptor alpha47, 
which is activated by the metabolite 27-hydrocholesterol, in arthritis. Jiang and colleagues have 
performed metabolomic profiling in order to identify the global metabolic defects associated with 
four different types of arthritis including OA, RA, gout and ankylosing spondylitis, compared to 
healthy controls. They found a common metabolic defect that is due to joint inflammation and 
lesions, as well as a unique metabolic signature for each type of arthritis. This highlights the 
potential of metabolomics for biomarker discovery and treatment stratifications. However, many of 
the studies based their conclusions on small sample sizes, lacked replication and stringent correction 
for multiple testing. Future studies should address these issues to find reliable biomarkers of disease 
progression and response to treatment. 
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Genetics 
There are three main aims behind any genetics study. The first is to identify proteins and pathways 
that are crucial to disease pathophysiology (e.g. OA) and increase our understanding of the 
condition. The second is to identify clinically relevant drug targets that can be manipulated 
pharmaceutically to prevent the disease (e.g. osteoporotic fractures). Finally, the third aim is to 
identify a set of variants that can be measured to determine which subject is at high risk (e.g. of 
future fracture). GWASes look for the association between common genetic variants -single 
nucleotide polymorphisms (SNPs), copy number variations (CNVs), indels - and specific phenotypes. 
In the past few years large-scale human GWASes of OA (>18000 samples48), RA (> 100000 samples49) 
have identified a substantial number of loci with several common pathway associated with 
prevalence, severity and progression of rheumatologic disease. More than 50 GWA studies found a 
total of 303 SNPs in 186 genes across all chromosomes that are associated with at least one 
rheumatic disease (Figure 6). These studies revealed that rheumatic diseases share common genetic 
risk factors, such as mutations in the tumor necrosis factor, alpha-induced protein 3 (TNFAIP3) gene, 
which are associated with RA49 , PsA50 and SLE51  The common genetic basis of these diseases is a 
likely reason for their comorbidities52. Common genetic causes also lead to similar symptoms, thus 
hindering the precise diagnosis of these diseases.  Metabolomics is closer to the actual disease 
phenotype (Figure 1) and can therefore be used to differentiate between diseases where genetics 
cannot. However, in many cases the molecular links between the genes/biochemical pathway and 
the disease remain unknown. Animal models have been performed to explore the mechanism 
underlying some of the genes identified for rheumatologic diseases. Studies in mice have been able 
to show the effect of TNFAIP3 on the inflammosome53, while  collagen-induced arthritis (CIA) mice 
were used to investigate the role of IGFBP3 in NF-κB signalling and its subsequent effect on RA54. 
Work on RUNX2 knockout mice explored their effect on OA by causing chondrocyte hypertrophy55. 
Researching the mechanisms of arthritis-related genes facilitates the discovery of drug targets, such 
as RUNX256  and IGFBP356. However, the lack of functional annotation for many genes adds another 
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limitation to genetics studies. Metabolomics can help overcoming this shortcoming by inferring 
genes functions57 and thus can provide further insights in potentially involved pathways.   
Some of the loci identified via GWAS meta-analysis48  lie in pathways known to be important in 
cartilage and bone physiology such as CHST11, RUNX2 and EGFBP3, while in other cases the gene 
function is unknown.  In cases whenthe aetiology of the link between a metabolite and disease onset 
or progression is known, it becomes feasible to make use of the metabolite in clinical research. On 
the other hand, this is not always needed for diagnosis and prognosis, as the is the case with anti-
citrullinated protein antibodies (ACPA) as a biomarker for RA, which are used in clinical routine in 
spite of a lack of their role in disease pathogenesis58 . 
GWASes for the metabolome 
A number of studies in the past few years have mapped genetic variation to plasma, serum and urine 
metabolites and have highlighted the genetic influence on these traits4-8. 
 Using metabolomics as a readout of molecular phenotypes allows the discovery of formerly 
undetected associations between diseases, genes and metabolic pathways. While biomarkers are 
useful for risk prediction and health assessment, the value of a biomarker increases substantially if it 
is causally involved in the manifestation of any arthritis condition. Combining genetic and 
metabolomics data allows for interesting modelling and statistical inference of causality.  
For instance, Mendelian randomisation is a statistical technique that allows to use genetic variation 
related to the risk factor of interest to re-assess observational estimates. The genetic variant acts as 
a proxy for the risk factor and the random allocation of genes during gamete production and 
fertilisation (Mendel Second law) is used as a natural experiment to show causation59. Being able to 
establish a causal link between a metabolite and disease or disease progression means that altering 
metabolite levels is directly relevant to disease management, and hence a target for intervention,  
rather than a simple by-product of disease. This is particularly relevant in the case of diseases such 
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as OA where no disease modifying drugs exist to date in spite of the very high prevalence and unmet 
medical burden. 
GWA studies have shown that, with the exception of HLA associations with autoimmune disorders, 
effect sizes are modest and large sample sizes, usually in the range of thousands are needed. On the 
other hand, current metabolomic studies for rheumatological diseases have been carried out at 
most a few hundred individuals (see Table 1 and Supplementary Table 1). 
Utilizing both genetic knowledge and metabolomics is achievable. By querying GWAS data for 
variants that regulate levels of metabolites and by developing databases of metabolomics profiling 
for various conditions on genotyped individuals it will be possible to establish  the links between 
genetic susceptibility and changes in metabolomics profiles in serum, urine, joint and bone tissue.  
To do this it will require being able to replicate findings in sufficiently large clinical cohorts of 
rheumatologically relevant traits assayed for the same metabolite panels and measured at 
comparable time points (e.g. pre/ post treatment).  As these data become available it will become 
possible to point out the genetic basis of metabolite links to disease progression or response to 
therapy and hence to understand the molecular pathways underlying these processes. 
IMPLICATIONS FOR THE FUTURE 
In addition, metabolomic analyses can provide information on current medication use (i.e. 
metabolites derived from specific drugs) and levels of these metabolites, if dosage is known, can 
inform variation in drug response between patients or help track compliance in clinical trials. They 
can also inform on smoking, as cotinine, a metabolic product of nicotine, is commonly measured by 
metabolomic panels.  
Metabolomics concentrates on small molecules. Other dynamic markers can also be integrated with 
this kind of data and should enrich our understanding of disease pathogenesis and improve disease 
diagnosis, prognosis and management in the future. We discuss two of these technologies: 
proteomics and metagenomics. 
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PROTEOMICS: The proteome includes all expressed proteins in a cell, tissue or organism and as such 
is a dynamic reflection of both genes and the environment. The human proteome map currently 
includes more than 84% of the annotated protein-coding genes in humans and 30,057 proteins 
derived from 17 adult and 6 foetal tissues (http://www.humanproteomemap.org/). It is a promising 
field for biomarker search as proteins are most likely to be ubiquitously affected in disease and 
disease response. Protein activity is indeed modulated by many factors besides the expression level 
of the relevant gene. Some direct and indirect approaches show promising results. For instance, 
emerging work on IgG glycosylation (the only post-translational modification that produces 
structural changes to proteins) has shown that patients with lupus have a significantly altered IgG 
glycome with decrease immunosuppressive action of circulating immunoglobulins compared to 
controls.60 
METAGENOMICS: Despite GWASes and GWAS meta-analyses of increasingly large samples, the 
variants identified for RA, for example, account for less than a third of the estimated heritability of 
RA and less than 5% of OA. This “missing heritability” may be explained in a number of ways 
including structural variation, rare variants, or by environmental factors influenced by host genetics. 
The microbial organisms resident on and within a human host – the microbiome - is one such 
potential contributor61. Microbes produce a range of enzymes, chemicals, hormones and vitamins 
that can potentially interact with our bodies. They also produce up to 1/3 of circulating metabolites 
and their presence in the gut is partly influenced by human genetic factors61. Under physiological 
conditions, there is a balance between the intestinal bacteria and the host. Disruption of this 
intricate system (dysbiosis) has been implicated in many human diseases including RA62.  Because 
the microbiome may be manipulated relatively easily with dietary or probiotic interventions it 
constitutes an attractive target for therapeutic intervention63. 
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CONCLUSIONS 
To date no published studies exist that combine a genetic and metabolomics approach to 
understand the pathogenesis of rheumatologic diseases. To a large extent this reflects the sparsity of 
metabolomics studies for the various forms of arthritis and the challenges posed by collecting 
relevant tissues (e.g. joint, bone, synovium) for cases and controls. Whereas genetics has delivered a 
remarkable wealth of knowledge on some types of arthritis, it has serious drawbacks, not least its 
non dynamic nature, and the modest effect sizes of any genes discovered (outside of the HLA for 
auto-immune disorders) and thus requires very large sample sizes. 
Harnessing the power of both, genetic knowledge and metabolomics, is however doable. By 
querying GWAS data for variants that regulate levels of metabolites and by developing databases of 
metabolomics profiling for various conditions on genotyped individuals it will be possible to establish 
the links between genetic susceptibility and changes in metabolomics profiles in serum, urine, joint 
and bone tissue.  This could help target pathways most likely to change over time or to improve 
early diagnosis or risk of progression. As the price of metabolomics decreases and it becomes 
increasingly feasible to measure hundreds of metabolites accurately, it will be used increasingly in 
rheumatology to assess drug levels and efficacy and could rapidly replace the more expensive clinical 
tests used today. 
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KEY POINTS 
 
• Large scale genetic association analyses have identified variants underlying genetic 
 architecture of various forms of arthritis but, with the exception of HLA loci, effect sizes are 
 small. 
• Metabolomics is a promising field both to investigate the molecular pathogenesis of 
 rheumatologic diseases and to track response to therapy. Few modest sized studies 
 have been conducted to date. 
• Metabolomics can accurately measure drug metabolites like ibuprofen and paracetamol and 
 other pain medications. 
 In order for metabolomics to yield its full potential the genetic contribution to metabolites 
 and to disease processes needs to be combined.   
• Combining different omics including microbiome and proteomics may aid to increase the 
 knowledge of pathways and diseases  
16 
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Figure legends. 
Figure 1. Metabolomic profiling as a tool in the study of rheumatological pathologies. The 
metabolites in circulation or found in tissues reflect on the one hand the genetic background and the 
gene expression in an individual, but also their lifestyle, diet, medication and exposures and the 
pathogenic processes ongoing. An integration with genetic profiling can help differentiate between 
molecular changes seen in a given joint disease derived from modifiable factors (i.e. dynamic 
changes that may respond to diet or medication) and those that are directly linked to an individual's 
genetic profile. They may also be used to track progression of disease and of treatment 
Figure 2. Two main approaches exist for carrying out metabolomic profiling: targeted and 
untargeted. The scope of these two types of analysis is different and they both have advantages and 
disadvantages. Untargeted metabolomics profiling is almost exclusively carried out using MS 
methods 
Figure 3.  Metabolomic profiling can be carried out in almost any type of biospecimen. The 
availability of joint or bone tissues is a major challenge. On the other hand, data from serum or urine 
may not be directly relevant to specific pathogenic processes.  
Figure 4. Statistical approaches to analyse metabolomics data 
Figure 5.  Publication statistics. Number of publications that were indexed in pubmed per year since 
2000 referring to GWASs (keywords “GWAS”, “genome-wide association”) and metabolomics 
(keywords “metabolomics”, “metabonomics”, “metabolic profiling”), respectively. 
Figure 6.  Genetic basis of rheumatoid diseases 
The figure summarises genetic associations with rheumatoid diseases listed in the GWAS catalogue. 
We included all SNPS that are associated with one of the diseases of interest at genome-wide 
significant (p<5*10-8), leaving 303 SNPs from 56 studies. SNP names and the associated genes were 
added for the SNPs with the highest p-values in each bin of 107bp. The associations were retrieved 
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from the GWAS catalogue (https://www.ebi.ac.uk/gwas) using the catalogue traits “osteoarthritis” 
and “osteoarthritis, knee” for OA, “psoriatic arthritis” and “psoriasis” for PsA, “rheumatoid arthritis” 
for RA, “gout” and “gout, urate measurement” for gout and “systemic lupus erythematosus”, 
“interferon alpha measurement, systemic lupus erythematosus”, “neonatal systemic lupus 
erythematosus", “systemic lupus erythematosus, lupus nephritis” and “systemic scleroderma, 
systemic lupus erythematosus” for lupus. The retrieved studies include (but are not limited to) 
studies on OA using 7410 cases and 11009 controls48, on PsA based on 4212 cases and 8032 
controls64, on RA based on 29880 cases and 73758 controls from different ancestries49, on gout using 
4275 cases and 6272 controls65 and studies on SLE based on 1311 cases and 2240 controls from 
European ancestry66 (and 1656 cases with 3394 controls with Chinese ancestry 51, respectively. 
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Table 1 – Examples of metabolomics studies investigating rheumatic diseases. Further details on 
the key studies are found in Supplementary Table 1.  
Disease 
# 
studies 
Study design 
# metabolites 
studied 
Platform 
used 
Fluid/tissue 
studied 
Key studies  
OA  61 
Case control 
(range n=50 to 
300 per group), 
progressors vs 
non progressors 
(n=22 per group) 
Untargeted 
NMR signals* 
(>40,000) 
Targeted 55-
228 
Targeted 
NMR, 
untargeted 
NMR, GC-MS 
Urine, 
plasma, 
serum knee 
synovial 
fluid 
Lamers 2005 
67 
Mickiewicz 
201568 
Zhang 201622 
Loeser 201621 
Zhai 201040 
RA 87 
Response to 
anti-TNF 
treatment 
(n<=30), 
prospective 
study of early RA 
(n=216), case-
control (n~55 
per group) 
Untargeted 
NMR signals* 
(>40,000) 
Targeted 194 
Targeted 
NMR, 
untargeted 
NMR, GC-MS 
serum 
Priori 201545 
Zabek 201620 
Young 201341 
Zhou 201669 
SLE 32 
Case control 
(range n=20-80 
per group) 
Targeted  81-
319 
Targeted LC-
MS 
Targeted GC-
MS  
Targeted 
NMR 
Serum, 
urine, 
peripheral 
blood 
lymphocytes 
Young 201341 
Wu 201242 
Ouyang 
201170 
Yan 201638 
Yan 201671 
PsA 18 
Case control 
(range n=10-32 
per group) 
Response to 
therapy (range 
n=10-32) (anti 
TNF, steroids) 
Targeted 9-
354 
Targeted GC-
MS 
Targeted LC-
MS 
Targeted 
NRM 
 
Serum, 
urine, 
plasma, skin 
Armstrong 
201419, 
Kapoor 20133, 
Kamleh 
201544, 
Sitter 201372 
gout 17 
Case control 
(n=21) 
Population 
based urate 
levels 
Targeted 27-
355 
Targeted  LC-
MS, GC-MS 
HPLC  diode 
array 
detector 
serum and 
urine 
Liu 201173, 
Albrecht 
201474 
* number of data points used in the NMR data processing 
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Supplementary Table 1 – Examples of metabolomics studies investigating rheumatic diseases. 
Pheno # studies Study design 
# metabolites 
studied 
Platform used Fluid studied Key Findings REF  
OA  61 
45 cases and 47 
controls 
65000 NMR 
signals 
NMR Urine 
 - urine metabolite profiles discriminate between cases and controls 
 - metabolite profiles differ by OA severity 
 - changes in histidine metabolism 
Lamers 2005 
67
 
55 cases, 13 (post-
mortem) controls 
55 NMR + GC-MS 
knee synovial 
fluid  
 - fructose and citrate increased  in cases, -acetylcarnitine, N-
phenylacetylglycine, methionine, ethanol, creatine, malate, ethanolamine, 3-
hydroxybutyrate and hexanoylcarnitine decreased in cases 
 - multivariate analysis perfectly distinguishes between cases and controls 
Mickiewicz 2015
68
 
64 cases and 45 
controls, replicated 
in 72 cases and 76 
controls 
186 MS (Biocrates) plasma 
 - 1 amino acid, 4 phosphatidylcholines and one sphingomyleine significantly 
different between cases and controls after replication 
 - arginine levels of <=57mM predict OA cases with 98.3% sensitivity and 89% 
specificity 
Zhang 2016
22
 
prospective study 
with 22 progressors 
and 22 age- and sex-
matched non-
progressors 
228 NMR urine 
 - urine metabolite levls distinguishbetween progressors and non-progressors 
prospectively at baseline as well as at follow-up (18 month later) 
 - glycolate and hippurate are increased and trigonelline decreased in 
progressors 
 - histidine is increased in progressors at follow up 
Loeser 2016
21
 
123 cases and 299 
controls, replicated 
in 76 cases and 100 
controls 
163 (and their 
ratios) 
MS(Biocrates) serum 
 - ratios of valine/histidine and xleucine/histidine consistenly increased in OA 
patients 
- other BCAA suggestively associated with OA 
Zhai 2010
40
 
RA 87 
prospective study 
with 27 female 
patients to assess 
response to 
Etanercept 
16000 NMR 
peaks 
NMR serum 
 - metabolic profiling allows perfect separation of responders and non-
responders 
 - branched-chain amino acids, alanine, glutamine, tyrosine, and glucose levels 
increased in responders; 3-hydroxybutyrate depleated in responders 
Priori 2015
45
 
30 healthy controls 
and 20 RA cases 
(followed up after 
treatment with 
etanercept or 
adalimumab) 
47 599 NMR 
peaks 
NMR serum 
 - perfect separation of cases and controls based on (amongst others) 
branched chain amino acids, lactate, 3-hydroxyisobutyrate and histidine 
 - cases after treatment form new cluster, clearly distinguishable from cases as 
well as healthy controls 
Zabek 2016
20
 
16 patients with 
established RA, 14 
healthy controls and 
216 patients with 
early RA (followed-
 
NMR serum 
 - lipid profiles in early arthritis change with level of inflammation (based on C-
reactive protein) 
 - 3-hydroxybutyrate and lactate elevated in RA patients 
 - discrimination of RA progressors and non-progressors possible based on 
Acetylglycine, methylguanidine and lactate, but with low accuracy 
Young 2013
41
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up longitudinally) 
55 RA cases, 32 
controls 
194 GC-MS serum 
 - amino acids depleated in RA cases compared to controls 
 - several metabolites involved in glycolysis, TCA and Urea Cycle disturbed in 
RA cases 
Zhou 2016
69
 
SLE 32 
42 healthy controls 
and 36 SLE cases in a 
double-blind 
placebo-controlled 
trial with N-
acetylcysteine (NAC) 
treatment  
258 LC-MS 
peripheral 
blood 
lymphocytes 
 - major differenctes between cases and healthy controls in pyrimidine, 
pyruvate and pentose phosphat pathways 
 - metabolic profiles also associated with disease activity, measured by SLEDAI, 
BILAG and FAS 
 - Kynurenine reduced by treatment with N-acetylcysteine (NAC) compared to 
placebo 
Young 2013
41
 
20 cases and 9 
controls, replicated 
in 38 cases using 
different assays 
319 GC-MS + LC-MS serum 
 - reduced energy biogenesis in SLE cases, indicated by changes in glycolysis, 
TCA cycle, beta oxidation and amino acid metabolism 
 - increased ocidative stress in cases: peroxidation of fatty acids, gluthatione 
Wu 2012
42
 
64 SLE patients, 30 
RA patients and 35 
healthy controls 
 
NMR serum 
 - lower concentration of amino acids, sugar, glycerides and citrate in SLE and 
RA cases compared to controls 
 - SLE cases characterised by dyslipidemia (elevated LDL, depleated HDL) 
Ouyang 2011
70
 
28 cases, 47 controls 81 GC-MS urine 
 - cases and controls distinguishable with reasonable quality 
 - concentration of branched chain amino acid in urine differs significantly 
between cases and controls 
Yan 2016
38
 
80 cases, 57 controls 98 GC-MS serum 
 - clear separation possible between cases and healthy controls as well as 
active and inactive SLE cases 
 - significant differences in amino acid (particularly branched-chain), TCA and 
lipid metabolism 
 - 2-hydroxyisobutyrate levels elevated in active but not in inactive SLE cases 
Yan 2016
71
 
PsA 18 
10 psoriasis cases, 10 
cases with psoriasis 
and psoriatic arthritis 
and 10 healthy 
controls 
144 known + 
354 unknown 
GC-MS serum 
 - psoriasis cases have higher levels of  alpha ketoglutaric acid and lower levels 
of asparagine anf glutamine compared to controls 
 - psoriatic arthritis cases have higher levels of glucuronic acid compared to 
controls 
 -  higher concentration of lignoceric acid in psoriatic arthritis than patients 
with psoriasis 
Armstrong 2014
19
 
longitudinal study of 
16 RA cases and 20 
PsA cases before and 
during anti-TNF 
 
NMR urine 
 - urine metabolite profiles distinguish between baseline (RA and PsA) samples 
and after treatment samples as well as between different treatments 
Kapoor 2013
3
 
30 
 
therapy 
32 healthy controls, 
32 mild psoriasis 
cases, 32 severe 
psoriasis cases (latter 
before and after 
treatment wit 
Etanercept) 
94 LC-MS plasma 
 - mainly amino acid levels differ between cases and controls and correlate 
with severity of disease 
 - treatment with Etanercept reverses many differences between cases and 
controls 
Kamleh 2015
44
 
10 cases before and 
after treatment with 
emollient and the 
corticosteroid  
clobetasol 
propionate ointment  
9 NMR skin 
 - levels of myo-inositol and glucose elevated and levels of choline decreased 
in psoriatic skin compared to uninvolved skin, indicating high proliferation 
rates 
 - steroid treatment leads to assimilation of treated psoriatic skin to 
uninvolved skin 
Sitter 2013
72
 
gout 17 
21 gout cases and 21 
age- and sex-
matched controls 
27 peaks in 
serum and 39 
in urine 
High 
performance 
liquid 
chromatography-
diode array 
detector 
serum and 
urine 
 - clear separation of cases and controls possible with both, serum and urine 
metabolite profiles 
 - creatinine, uric acid and tryptophan increased in serum of cases 
 - hippuric acid and guanine decreased in urine of gout patients 
Liu 2011
73
 
cross-sectional with 
1764 individuals 
investigating serum 
urate levels 
355 
LC-MS, GC-MS 
(Metabolon) 
serum 
 - using gaussian graphical models reveals three modules involved in serum 
urate regulation: purine metabolites, amino acids and steroids 
Albrecht 2014
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The table summarises metabolomics studies investigating different rheumatic diseases. Studies were retrieved from Pubmed using the keywords “(metabolomics OR metabonomics OR 
metabolic profiling)” and “osteoartrithis” for OA, “rheumatoid arthritis” for RA, “lupus” for SLE, “psoriatic arthritis OR psoriasis” for PsA and gout. An exemplary selection of studies for each 
disease is briefly described. 
